4DMT to Participate in Upcoming Investor Conferences
November 15 2023 - 8:00AM
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the
Company), a genetic medicines company with three novel, highly
targeted next generation AAV vectors currently in human clinical
studies, announced today that management will participate in a
fireside chat at an upcoming investor conference in November.
Members of the management team will also be available for
one-on-one meetings in connection with this meeting.
6th Annual Evercore ISI HealthCONx
Conference
Presentation Date: |
Tuesday, November 28, 2023 |
Presentation Time: |
1:45 p.m. ET |
Webcast Link: |
Webcast |
Archived copies of the webcasts will be available for up to one
year by visiting the “Investors” section of the 4DMT website at
https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a clinical-stage genetic medicines company with three
novel, highly targeted next generation AAV vectors currently in
human clinical studies targeting multiple large market diseases in
ophthalmology and pulmonology, plus other therapeutic areas. 4DMT
seeks to unlock the full potential of genetic medicines using its
proprietary invention platform, Therapeutic Vector Evolution, which
combines the power of the Nobel Prize-winning technology, directed
evolution, with approximately one billion synthetic AAV
capsid-derived sequences to invent customized and evolved vectors
for use in our product candidates. All of our vectors are
proprietary to 4DMT and were invented at 4DMT, including the
vectors utilized in our clinical-stage and preclinical pipeline
product candidates: R100, A101, and C102. The Company is initially
focused on five clinical-stage product candidates in three
therapeutic areas for both rare and large market diseases:
ophthalmology, pulmonology, and cardiology. The 4DMT customized and
evolved vectors were invented with the goal of being delivered at
relatively low doses through clinically routine, well-tolerated,
and minimally invasive routes of administration, transducing
diseased cells in target tissues efficiently, having reduced
immunogenicity and, where relevant, having resistance to
pre-existing antibodies. 4DMT is currently advancing five product
candidates in clinical development: 4D-150 for wet AMD and DME,
4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease
cardiomyopathy, 4D-125 for XLRP, and 4D-110 for choroideremia. The
4D preclinical product candidates in development are: 4D-175 for
geographic atrophy and 4D-725 for AATLD.
4D-150, 4D-710, 4D-310, 4D-125, and 4D-110 are our product
candidates in clinical development and have not yet been approved
for marketing by the US FDA or any other regulatory authority. No
representation is made as to the safety or effectiveness of 4D-150,
4D-710, 4D-310, 4D-125, or 4D-110 for the therapeutic uses for
which they are being studied.
4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector
Evolution™, and the 4DMT logo are trademarks of 4DMT.
Contacts:
Media:
Katherine SmithEvoke CanaleKatherine.Smith@evokegroup.com
Investors:
Julian PeiHead of Investor Relations and Corporate
CommunicationsInvestor.Relations@4DMT.com267-644-5097
4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
From Apr 2024 to May 2024
4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
From May 2023 to May 2024